HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

States’ Proposals To Age-Restrict Sports Nutrition Sales Miss Targeted Problems But Hit Retailers

Executive Summary

MA and NY lawmakers propose prohibiting sales to consumers under 18 of supplements, OTC drugs for weight loss and muscle building and imposing $2,000 fines for violations. Supplement industry trade groups say the laws would not help solve eating disorders but would hammer retailers.

You may also be interested in...



New York’s Age Restrictions On Weight Loss, Sports Supplement Sales Fail To Fly

New York legislation to restrict sales of weight loss and sports nutrition supplements to minors failed without reaching a vote before the end of the session. But the proposal will continue to be a challenge for industry in New York as well as around the country.

CA Tries Again To Age-Restrict Workout Supplement Sales, MA On Energy Drinks

Massachusetts legislation proposes age-restricting energy drink sales and says violating parties will face fines between $50 and $250. California bill would prohibit sales of weight loss and workout products to minors, as is already proposed in New York and Massachusetts.

Legislation Adding SARMs to CSA Schedule III Introduced In Senate

“By placing SARMs on the same schedule as other anabolic steroid, we’re ensuring a safer and more transparent marketplace," says Iowa Republica Chuck Grassley, who sponsored the bill with Rhode Island Democrat Sheldon Whitehouse.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel